TreeFrog Therapeutics’ Post

Don’t miss the poster presentation by Scientific Officer @Michelle Miller, Ph.D., on Thursday, March 14th at #2024SOT in Salt Lake City. The focus will be on assessing pre-existing neutralizing anti-AAV antibodies as a strategy to improve translatability of preclinical AAV therapeutic studies. This approach is a critical part of screening animals prior to selection or stratification. Stop by the poster to discuss your upcoming gene and cell therapy project with Dr. Miller and explore our website to discover more about all of our immunoassay development and validation services. https://bit.ly/43cmLpu #ToxExpo #genetherapy #immunoassay #ligandbindingassay #assaydevelopment

Did you know that our model has a naturally low prevalence of circulating Nabs to AAVs? This means less subjects screened for inclusion, saving time, money and supporting the 3Rs. Come see us at booth 814 to learn more. Check out the link for more information! #AAV #research #scientificadvancements #virscio #ASCGT #cellandgenetherapy

Social Pharma Patient-Centric Marketing socialpharma.net >>> Gene&Cell Therapy >> ProKidney axes one Phase 3 study, aims for 'expedited approval pathway' using another #lucidquest #genetherapy #celltherapy

#Cardiometabolic risk factors are still among the leading drivers of both global mortality and morbidity. Over the past 5 years, the number of clinical-stage cardiometabolic assets has increased by 13%, and today, it accounts for 7% of the overall industry R&D pipeline. This includes cell, gene and RNA therapeutics. Explore the latest trends in cardiometabolic breakthroughs, the market opportunity, and critical success factors for innovators. Download the white paper to learn more: https://bit.ly/3ZeOCWf #obesity #clinicaltrials

Thrilled to share I've been featured in the latest issue of Drug Discovery World, discussing 2024 predictions in collaboration with Megan Thomas. We dove deep into the dynamic landscape of cell and gene therapy, revealing its potential to significantly advance treatment options for hard-to-treat diseases.    Check out the full article (pages 8-9 specifically) to explore the groundbreaking insights shaping the future of healthcare.    #drugdiscovery #2024predictions #cellandgenetherapy #healthcareinnovation

The new year is here, and with it comes a fresh wave of predictions for the drug discovery industry. In this issue of Drug Discovery World, Megan Thomas spoke with industry experts about the opportunities and challenges that lie ahead in 2024. One of the most exciting trends is the continued rise of cell and gene therapy (CGT). Josh Ludwig, Global Director, Commercial Operations at ScaleReady, believes CGT has the potential to revolutionize healthcare for patients with hard-to-treat diseases. Read the full article on pages 8-9 here: https://lnkd.in/d5AAYUpu What are your thoughts on the future of drug discovery? Share your predictions in the comments below. #cellandgenetherapy #CGT #healthinnovation #medtech

Although cancer-causing gene fusions result from DNA level changes, not all DNA fusions are relevant at the RNA and protein levels. In this application note from Twist Bioscience and CeGaT, learn about fusion detection panels that cover relevant targets for therapeutic development, tumor diagnostics, and beyond. #AD https://ow.ly/t5Rz50SXan6

👀 We are loving Drug Discovery World’s new Winter issue! Don’t miss the Therapeutic Antibodies Guide covering articles on a variety of topics ranging from therapeutic antibodies in the fight against Alzheimer's to accelerating gene synthesis times for speedy antibody discovery. #antibody #antibodies #antibodydiscovery #DNA Twist Bioscience

Interested in learning about select scalable GMP ancillary materials to enhance your control over quality and safety standards? Fill out this form to watch our webinar about regulatory requirements for GMP ancillary materials and the importance of regulatory documentation and support to enable successful clinical translation of cell and gene therapies.

Interested in learning about select scalable GMP ancillary materials to enhance your control over quality and safety standards? Fill out this form to watch our webinar about regulatory requirements for GMP ancillary materials and the importance of regulatory documentation and support to enable successful clinical translation of cell and gene therapies.